Showing 1 - 20 of 32 Items
Showing 1 - 20 of 32 Items
Sort By: Relevance
Journal Article
|Research
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine
BACKGROUND
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...
Conference Material
|Slide Presentation
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|Video
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|Abstract
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...
Journal Article
|Letter
2024-05-02 • Antimicrobial Agents and Chemotherapy
2024-05-02 • Antimicrobial Agents and Chemotherapy
Journal Article
|Research
2024-01-29 • medRxiv
2024-01-29 • medRxiv
BACKGROUND
Aft...
Journal Article
|Protocol
2023-11-30 • Trials
2023-11-30 • Trials
BACKGROUND
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yi...
Conference Material
|Slide Presentation
2023-11-15 • The Union World Conference on Lung Health 2023
2023-11-15 • The Union World Conference on Lung Health 2023
Technical Report
|Evidence Brief
2023-11-15
2023-11-15
Each year there are approximately 500,000 new cases of multidrug-resistant tuberculosis (MDR-TB) worldwide, but only a tiny fraction is successfully treated. The endTB trial, led by Méde...
Journal Article
|Research
2023-10-30 • Frontiers in Oncology
2023-10-30 • Frontiers in Oncology
INTRODUCTION
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy. While the survival rate for childhood ALL exceeds 90% in high-income countries, the estimated...
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy. While the survival rate for childhood ALL exceeds 90% in high-income countries, the estimated...
Journal Article
|Research
2023-09-01 • NEJM Evidence
2023-09-01 • NEJM Evidence
BACKGROUND
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...
Shorter but effective tuberculosis treatment regimens would be of value to the tuberculosis treatment community. High-dose rifampicin has been associated with more rapid a...
Journal Article
|Research
2023-06-01 • Public Health Nutrition
2023-06-01 • Public Health Nutrition
OBJECTIVE
To compare the prognostic value of mid-upper arm circumference (MUAC), weight-for-height Z-score (WHZ) and weight-for-age Z-score (WAZ) for predicting death over periods of...
To compare the prognostic value of mid-upper arm circumference (MUAC), weight-for-height Z-score (WHZ) and weight-for-age Z-score (WAZ) for predicting death over periods of...
Journal Article
|Research
2023-02-03 • Public Health Nutrition
2023-02-03 • Public Health Nutrition
OBJECTIVE
To understand which anthropometric diagnostic criteria best discriminate higher from lower risk of death in children and explore programme implications.
DESIGN
To understand which anthropometric diagnostic criteria best discriminate higher from lower risk of death in children and explore programme implications.
DESIGN
Journal Article
|Research
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Conference Material
|Poster
2022-11-30 • MSF Paediatric Days 2022
2022-11-30 • MSF Paediatric Days 2022
Journal Article
|Short Report
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Journal Article
|Letter
2021-02-17 • International Journal of Health Planning and Management
2021-02-17 • International Journal of Health Planning and Management
Journal Article
|Commentary
1993-05-08 • British Medical Journal (BMJ)
1993-05-08 • British Medical Journal (BMJ)
Journal Article
|Protocol
2021-09-25 • Trials
2021-09-25 • Trials
BACKGROUND
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. W...
Protocol
|Research Protocol
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...